Valuation dashboard for Novocure Ltd (NVCR) with P/E N/A, P/B 5.08, EV/EBITDA -15.48 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Analysis Summary
Novocure Ltd reported revenue of $655.4M in the most recent fiscal year, growing at a 5-year CAGR of 5.8%.
Trailing-twelve-month margins: gross margin 76.1%, operating margin -22.1%, net margin -21.2%.
At the current price of $15.20, NVCR has negative trailing earnings (P/E not meaningful) and an ROE of -44.00%. Market capitalisation stands at $1.8B.
Balance sheet quality for NVCR: current ratio of 2.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 5.08 |
| EV / EBITDA | -15.48 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-24.80 |
| vs Current Price | -263.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NVCR | Novocure Ltd | $1.7B | 5.08 | -44.0% | |
| NEOG | Neogen Corporation | $2.6B | 1.26 | -0.4% | |
| PLSE | Pulse Biosciences, Inc. | $3.4B | 33.31 | -90.2% | |
| ABT | Abbott Laboratories | $168.7B | 31.35 | 3.33 | 12.5% |
| 0Y6X.L | Medtronic Plc | $118.6B | |||
| MDT | Medtronic plc | $110.6B | 21.28 | 2.20 | 9.7% |
| 0R2S.L | Stryker Corporation | $106.3B | 29.31 | 4.56 | 16.4% |
| SYK | Stryker Corporation | $105.6B | 28.54 | 4.40 | 14.5% |
Price
| Price | $15.20 |
| Market Cap | $1.8B |
| Exchange | NASDAQ |
| Country | CH |
Profitability
| Return on Equity | -44.00% |
| Return on Invested Capital | -26.15% |
| Return on Assets | -18.68% |
| Gross Margin | 76.13% |
| Operating Margin | -22.08% |
| Net Margin | -21.25% |
Related companies: AZTA · BLFS · ESTA · EVO · KMTS · NEOG · PLSE
Explore sector: Healthcare · Medical - Devices
More sections of NVCR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks